Compare Charles River Laboratories Intl. Inc (CRL) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Quantumscape Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $231.18 (market cap $11.14B), while Quantumscape Corp trades at $6.67 (market cap $3.95B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.8× Quantumscape Corp's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| CRL | QS | |
|---|---|---|
Market Cap | $11.14B | $3.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $18.44 |
52-Week Low | $145.57 | $5.96 |
Enterprise Value | $14.00B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
QuantumScape (QS) trades at $6.28, down 4.56% today, with a bearish technical outlook and negative profitability metrics. The company reported a net loss of $435.05M in 2025 and relies on financing cash flows to fund operations. Recent news highlights a joint research agreement with Honda, providing a potential catalyst for its solid-state battery technology development.
The outlook remains speculative with high execution risks as QS transitions from R&D to commercialization. Analyst sentiment is cautious with 73% hold ratings. Investment opportunity hinges on successful battery commercialization, but risks include persistent losses, competitive threats, and reliance on external funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
